What is the efficacy of the combination of vepotuzumab/urovax?

Polatuzumab is an innovative antibody-drug conjugate (ADC) that specifically targets the B cell surface antigen CD79b and accurately delivers the cytotoxic drug monomer MMAE to malignant B cells, thereby achieving targeted killing and minimizing damage to normal cells. Its unique mechanism enables it to show obvious clinical potential in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL; non-Hodgkin lymphoma). Although monotherapy has certain efficacy, studies have shown that velpotuzumab combined with rituximab (Rituximab) and chemotherapy regimens (such as Bendamustine or CHP regimen) can significantly enhance the anti-tumor effect.

The combination regimen can work synergistically through multiple mechanisms: on the one hand, rituximab targetsCD20 antigen to induce antibody-dependent cytotoxicity (ADCC) and complement-dependent cytolysis (CDC), further promoting B cell apoptosis; on the other hand, chemotherapy drugs provide a microenvironment for antibody conjugate drugs to be more susceptible to killing by destroying DNA synthesis and cell division. Clinical studies show that Polatuzumab vedotin combined with rituximab and chemotherapy improves the overall response rate (ORR) and complete response rate (CR) in patients with relapsed or refractory DLBCL, and has higher efficacy than traditional single-drug or double-drug treatment regimens. In addition, this combination regimen can improve patients' quality of life, extend progression-free survival (PFS), and provide a new treatment option for advanced or relapsed patients.

The advantages of combination therapy are not only reflected in the efficacy, but also include the applicability to some high-risk patient groups (such as elderly patients and patients with low chemotherapy tolerance). By precisely targetingB cells and controlling drug release, vepotuzumab can maximize the killing of malignant cells while reducing systemic toxicity. Despite this, combined medication still needs to be implemented in strict accordance with guidelines and physician guidance. Because of its potential risk of bone marrow suppression and immunosuppression, blood and infection conditions need to be closely monitored.

Reference materials:https://www.drugs.com/polivy.html